Intellia Therapeutics (NTLA) Operating Income: 2015-2025
Historic Operating Income for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -$111.5 million.
- Intellia Therapeutics' Operating Income rose 23.00% to -$111.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$478.7 million, marking a year-over-year increase of 10.97%. This contributed to the annual value of -$534.3 million for FY2024, which is 3.68% down from last year.
- Per Intellia Therapeutics' latest filing, its Operating Income stood at -$111.5 million for Q3 2025, which was down 1.35% from -$110.0 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' Operating Income ranged from a high of -$46.4 million in Q1 2021 and a low of -$144.8 million during Q3 2024.
- In the last 3 years, Intellia Therapeutics' Operating Income had a median value of -$131.1 million in 2023 and averaged -$126.5 million.
- Its Operating Income has fluctuated over the past 5 years, first tumbled by 210.71% in 2022, then grew by 23.00% in 2025.
- Quarterly analysis of 5 years shows Intellia Therapeutics' Operating Income stood at -$80.4 million in 2021, then crashed by 36.90% to -$110.1 million in 2022, then dropped by 27.07% to -$139.9 million in 2023, then increased by 2.46% to -$136.4 million in 2024, then climbed by 23.00% to -$111.5 million in 2025.
- Its last three reported values are -$111.5 million in Q3 2025, -$110.0 million for Q2 2025, and -$120.8 million during Q1 2025.